KMDA Earnings Date: Nov 9, 2026 (Estimated) — Kamada Ltd.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
Updated
When is KMDA's next earnings date?
Kamada Ltd. (KMDA) is expected to report Q3 2026 earnings on Monday, November 9, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.13 on revenue of $52.5M.
How did KMDA do in its last earnings report?
In its most recent report on Aug 12, 2026 (Q2 2026), Kamada Ltd. posted EPS of $0.16 versus the $0.11 estimate, a beat of 45.5%. Revenue was $54.9M against a $50.8M estimate. The stock's 1-day post-earnings move was -3.0%.
How much does KMDA stock move after earnings?
KMDA beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 4.5% (up or down) in the day after earnings.
About Kamada Ltd.
Kamada Ltd. is a biopharmaceutical firm focused on developing, manufacturing, and distributing protein therapeutics derived from human plasma. The company operates through two core business areas: its proprietary product segment and its distribution division. Its own manufactured portfolio includes KAMRAB/KEDRAB for rabies prevention, CYTOGAM to prevent cytomegalovirus disease in transplant recipients, WINRHO SDF for immune thrombocytopenic purpura and Rhesus (Rh) isoimmunization, HEPAGAM B for hepatitis B recurrence prevention following liver transplants and for post-exposure prophylaxis, VARIZIG for post-exposure chickenpox prophylaxis, and GLASSIA for intravenous alpha-1 antitrypsin deficiency (AATD). Kamada also produces KamRho (D) for the prophylaxis of hemolytic disease of newborns and immune thrombocytopenic purpura, along with a specific antiserum for Vipera palaestinae and Echis coloratus snake bites. Additionally, the company distributes a wide array of third-party pharmaceutical products, encompassing treatments like BRAMITOB for chronic pulmonary infections, FOSTER for asthma, PROVOCHOLINE for diagnosing bronchial airway hyperactivity, and specialized therapies such as IVIG for immunodeficiency, VARITECT for chickenpox and zoster herpes, and various factors for hemophilia A and B, among numerous others for conditions like hepatitis B, cytomegalovirus, angioedema, Japanese encephalitis, and prostate cancer. Kamada markets its offerings in the United States through strategic partners and internationally via a network of distributors. The company maintains significant collaborations with Takeda Pharmaceuticals Company Limited, PARI GmbH, and Kedrion Biopharma. Established in 1990, Kamada Ltd. is headquartered in Rehovot, Israel.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-12 | Q2 2026 | 0.11 | 0.16 | +45.45% | $54.9M | ✅ Beat | -2.96% | +11.29% | +14.44% |
| 2026-05-13 | Q1 2026 | 0.12 | 0.07 | -41.67% | $45.2M | ❌ Miss | -6.77% | -9.85% | -11.74% |
| 2026-03-11 | Q4 2025 | 0.08 | 0.06 | -25.00% | $44.7M | ❌ Miss | -4.58% | -0.78% | -2.87% |
| 2025-11-10 | Q3 2025 | 0.10 | 0.09 | -10.00% | $47.0M | ❌ Miss | +5.41% | +4.96% | +2.25% |
| 2025-08-13 | Q2 2025 | 0.09 | 0.13 | +44.44% | $38.4M | ✅ Beat | -1.35% | -3.21% | -6.22% |
| 2025-03-05 | Q4 2024 | 0.05 | 0.07 | +40.00% | $39.0M | ✅ Beat | +7.41% | +7.72% | +3.67% |
| 2024-11-13 | Q3 2024 | 0.07 | 0.07 | +0.00% | $41.7M | ➖ Inline | -3.82% | -5.73% | -7.65% |
| 2024-08-14 | Q2 2024 | 0.06 | 0.08 | +33.33% | $42.5M | ✅ Beat | -3.96% | +1.26% | -2.33% |
Showing last 8 quarters.
Revenue by segment & region
By region
Q4 FY21 · $4.6M total
| Segment | Share | Revenue | YoY | Q4 FY21 |
|---|---|---|---|---|
| OtherForeignCountriesThreeMember | 98.9% | $4.6M | — | $4.6M |
| OtherCountriesMember | 1.1% | $53K | — | $53K |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.